PIQUR

OFFICIAL TITLE: AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTRE PHASE 1/ 2B STUDY INVESTIGATING SAFETY AND EFFICACY OF PQR309 AND ERIBULINCOMBINATION IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2 NEGATIVE AND TRIPLE-NEGATIVE BREAST CANCER.

PROJECT DETAILS

THIS STUDY IS AN OPEN-LABEL,NON RANDOMIZED, MULTI-CENTER, PHASE 1/2B (DOSE ESCALATION FOLLOWED BY EXPANSION PART) STUDY EVALUATING CLINICAL SAFETY, EFFICACY AND PHARMACOKINETICS OF PQR309 IN COMBINATION WITH STANDARD DOSE OF ERIBULIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE (ESCALATION PART) AND TRIPLE NEGATIVE BREAST CANCER (EXPANSION PART).

LEGAL STUDY SPONSOR IS PIQUR THERAPEUTICS AG

 

PIQUR AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

BREAST

I/IIb

43

6

Spain, UK

N

SITES

COUNTRY

STATUS

Recruitment  closed

SABCS 2016 – DOWNLOAD THE POSTER

PIQUR SITES

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Instituto Valenciano de Oncología (IVO)

SPAIN

Hospital Universitari Vall D'Hebron

SPAIN

Institut Català d' Oncologia L'Hospitalet (ICO)

UK

Churchill Hospital, Oxford

UK

Barts Cancer Institute